Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Ipsen S.A. press release ( OTCPK:IPSEY ): FY Non-GAAP EPS of €10.51. Revenue of €3.02B (+14.4% Y/Y). 2022 core operating margin of 36.9%, broadly in line with 2021. 2023 financial guidance : total-sales growth greater than 4.0% at CER1 ; core operat...
Summary The backbone of the Albireo is Bylvay, a product in a platform already approved in one indication and expected to be approved in two significant larger indications. Ipsen recognizes the huge potential and is offering $42 plus a $10 CVR to acquire Albireo. The deal is expected to...
Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...
A committee of the European Medicines Agency (EMA) declined to recommended Ipsen's ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) drug palovarotene to treat a rare bone disorder. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended not to grant marketing author...
Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U. FOP is an ultra-rare disease that continuously and permanently causes abnormal bone formation. 1 There are currently no disease-modifying treatment op...
Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) presented full data from a phase 3 trial showing that its drug Onivyde helped improve overall survival (OS) and progression-free survival (PFS) in patients with a type of pancreatic cancer. The French drugmaker had initially reported ...
Investigational Onivyde ® (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile 1 Result...
Transaction focused on Bylvay ® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen’s long-term strategy for expanding the scope of its Rare Disease p...
Summary In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share. After adjusting for NOLs, tax inte...
The U.S. FDA has declined to approve palovarotene developed by French pharma company Ipsen S.A. ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) to reduce abnormal bone formation in people living with ultra-rare disease fibrodysplasia ossificans progressiva (FOP). The FDA has communicated its decision...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...